Research Output per year
Research Output per year
Personal profile
Research Interests
I am interested in using quantitative pharmacologic approaches (modeling and simulation) to improve the understanding of drug disposition and effects in children. Pharmacometric interpretation of both population and clinical trial data can lead to more efficacious and safer treatments as well as provide guidance for the design of efficient, definitive pediatric clinical trials.
Pharmacometrics, Pediatric Clinical Pharmacology
Pediatric Critical Care Medicine, Pediatric Pulmonary Medicine
Certifications and Licenses
| Pediatric Pulmonology | |
| Pediatric Critical Care Medicine | |
| Pediatrics |
Training Experience
| 1975 | Internship, University of Minnesota Medical Center |
| 1977 | Residency, University of Minnesota Medical Center |
| 1979 | Fellowship, University of Minnesota Medical Center |
| 1994 | Fellowship, University of North Carolina School of Medicine |
| 1994 | Fellowship, University of Minnesota Medical Center |
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
MD, Medicine, Stanford University
… → 1974
Research interests keywords
- Clinical Pharmacology
- Critical Care
- Pediatrics
- Pharmacokinetics
- Pharmacology
- Respiratory Diseases
Fingerprint
Dive into the research topics where Thomas P Green is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Characterizing Enoxaparin’s Population Pharmacokinetics to Guide Dose Individualization in the Pediatric Population
the Best Pharmaceuticals for Children Act-Pediatric Trials Network Steering Committee, Jul 2024, In: Clinical Pharmacokinetics. 63, 7, p. 999-1014 16 p.Research output: Contribution to journal › Article › peer-review
-
Physiologically-based pharmacokinetic modeling of pantoprazole to evaluate the role of CYP2C19 genetic variation and obesity in the pediatric population
the Best Pharmaceuticals for Children Act-Pediatric Trials Network Steering Committee, Aug 2024, In: CPT: Pharmacometrics and Systems Pharmacology. 13, 8, p. 1394-1408 15 p.Research output: Contribution to journal › Article › peer-review
Open Access3 Scopus citations -
Postdiscontinuation Antibiotic Exposure in Hospitalized Infants at Risk for Late-onset Sepsis in the Neonatal Intensive Care Unit
Administrative Core Committee of the Best Pharmaceuticals for Children Act - Pediatric Trials Network, Oct 1 2024, In: Pediatric Infectious Disease Journal. 43, 10, p. 991-996 6 p.Research output: Contribution to journal › Article › peer-review
-
The Reviewer Academy of the Society of Critical Care Medicine: Key Principles and Strategic Plan
Alexander, P. M. A., Aslakson, R. A., Barreto, E. F., Lee, J. H., Meissen, H., Morrow, B. M., Nazer, L., Branson, R. D., Mayer, K. P., Napolitano, N., Lane-Fall, M. B., Sikora, A., John, P. R., Dellinger, R. P., Parker, M., Argent, A., Boateng, A., Green, T. P., Kudchadkar, S. R. & Maslove, D. M. & 5 others, , Sep 1 2023, In: Critical care medicine. 51, 9, p. 1111-1123 13 p.Research output: Contribution to journal › Article › peer-review
Open Access4 Scopus citations -
Use of Real-World Data and Physiologically-Based Pharmacokinetic Modeling to Characterize Enoxaparin Disposition in Children With Obesity
the Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee, Aug 2022, In: Clinical pharmacology and therapeutics. 112, 2, p. 391-403 13 p.Research output: Contribution to journal › Article › peer-review
Open Access17 Scopus citations